Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
|
By LabMedica International staff writers Posted on 05 Feb 2020 |

Illustration
Randox Biosciences, a part of Randox Laboratories, (Crumlin, UK), showcased its new Vivalytic molecular diagnostic platform at MEDLAB Middle East, the largest medical laboratory exhibition and congress in the Middle East & North Africa (MENA) region.
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Latest MEDLAB 2020 News
- Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
- EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channelGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read more
Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more








